Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
BioProcess Internation...BioProcess International
Not Confirmed
Not Confirmed
22-26 September, 2024
SPE Annual TechnicalSPE Annual Technical
Not Confirmed
Not Confirmed
23-25 September, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
BioProcess Internation...BioProcess International
Industry Trade Show
Not Confirmed
22-26 September, 2024
SPE Annual TechnicalSPE Annual Technical
Industry Trade Show
Not Confirmed
23-25 September, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-re-unlocking-life-changing-potential-in-complex-molecules-without-sacrificing-time-to-market
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
07 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/serviers-voranigo-vorasidenib-tablets-receives-fda-approval-as-first-targeted-therapy-for-grade-2-idh-mutant-glioma-302215991.html
30 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/servier-initiates-critical-dialogue-on-aya-cancer-survivorship-at-asco-2024-302158733.html
23 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/servier-highlights-commitment-to-improving-cancer-outcomes-at-asco-2024-302153468.html
14 May 2024
// Nick Paul Taylor FIERCE PHARMA
https://www.fiercepharma.com/marketing/et-voila-new-name-takes-top-spot-reputation-ranking-us-patient-groups
14 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/servier-ranks-1st-across-several-categories-in-2023-2024-patientview-us-corporate-reputation-survey-302144762.html
18 Apr 2024
// 20MINUTES
https://www.20minutes.fr/economie/4087038-20240418-biogaran-poids-lourd-francais-medicaments-generiques-vendu-groupe-etranger
Details:
Voranigo (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor IDH1/2 enzymes. It is approved by FDA for the treatment of IDH-mutant diffuse glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Brand Name: Voranigo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2024
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Servier’s VORANIGO® Receives FDA Approval as First Targeted Therapy for IDH Glioma
Details : Voranigo (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor IDH1/2 enzymes. It is approved by FDA for the treatment of IDH-mutant diffuse glioma.
Brand Name : Voranigo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 06, 2024
Details:
AG-881 (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes. It is being evaluated for the treatment of IDH-mutant diffuse glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Brand Name: AG-881
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AG-881 (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes. It is being evaluated for the treatment of IDH-mutant diffuse glioma.
Brand Name : AG-881
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 20, 2024
Details:
The agreement aims to develop RNA-targeted small molecule therapeutics by leveraging Base4's pioneering drug discovery platform to identify RNA-modulating small molecules to enable and accelerate Servier's research in neuroscience drug candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Small molecule
Recipient: Base4 Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Recipient : Base4 Biotechnology
Deal Size : Undisclosed
Deal Type : Agreement
Servier and Base4 Expand Partnership to Advance Neuroscience Drug Development
Details : The agreement aims to develop RNA-targeted small molecule therapeutics by leveraging Base4's pioneering drug discovery platform to identify RNA-modulating small molecules to enable and accelerate Servier's research in neuroscience drug candidates.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2024
Details:
AG-881 (vorasidenib) is an oral, brain-penetrant, dual inhibitor of mutant (m)IDH1/2 enzymes. It is being evaluated for the treatment of IDH-Mutant Diffuse Glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Brand Name: AG-881
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2023
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AG-881 (vorasidenib) is an oral, brain-penetrant, dual inhibitor of mutant (m)IDH1/2 enzymes. It is being evaluated for the treatment of IDH-Mutant Diffuse Glioma.
Brand Name : AG-881
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 18, 2023
Details:
Tibsovo (ivosidenib) tablet is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 enzyme, which is investigated for IDH1-mutated Relapsed or refractory myelodysplastic syndromes.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Brand Name: Tibsovo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Lead Product(s) : Ivosidenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for the Treatment of IDH1-Mutated...
Details : Tibsovo (ivosidenib) tablet is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 enzyme, which is investigated for IDH1-mutated Relapsed or refractory myelodysplastic syndromes.
Brand Name : Tibsovo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2023
Details:
TIBSOVO® (ivosidenib) tablet is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 enzyme, which is investigated for IDH1-mutated Relapsed or refractory myelodysplastic syndromes.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Brand Name: Tibsovo
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Lead Product(s) : Ivosidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in ...
Details : TIBSOVO® (ivosidenib) tablet is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 enzyme, which is investigated for IDH1-mutated Relapsed or refractory myelodysplastic syndromes.
Brand Name : Tibsovo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2023
Details:
Aitia and Servier will focus to discover, validate, and strive to develop novel drug targets and candidates in pancreatic cancer by utilizating Aitia's Pancreatic Cancer Digital Twins and Servier's pre-clinical assays, therapeutic creation platforms, and expertise.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Aitia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 17, 2023
Details : Aitia and Servier will focus to discover, validate, and strive to develop novel drug targets and candidates in pancreatic cancer by utilizating Aitia's Pancreatic Cancer Digital Twins and Servier's pre-clinical assays, therapeutic creation platforms, and...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
May 17, 2023
Details:
Tibsovo® (ivosidenib tablets) is the first and only IDH1 inhibitor approved in Europe. It has received orphan medicine designation recognizing the significant benefit brought to patients by Tibsovo® over available therapies for both CCA and AML.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Brand Name: Tibsovo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Lead Product(s) : Ivosidenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Servier Receives European Commission Approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Ac...
Details : Tibsovo® (ivosidenib tablets) is the first and only IDH1 inhibitor approved in Europe. It has received orphan medicine designation recognizing the significant benefit brought to patients by Tibsovo® over available therapies for both CCA and AML.
Brand Name : Tibsovo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 10, 2023
Details:
AG-881 (vorasidenib) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes. It is beinf developed for the treament of IDH-mutant low-grade glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Brand Name: AG-881
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Lead Product(s) : Vorasidenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AG-881 (vorasidenib) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes. It is beinf developed for the treament of IDH-mutant low-grade glioma.
Brand Name : AG-881
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 14, 2023
Details:
Tibsovo (ivosidenib) is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. In patients with AML, susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leukemia cells.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Brand Name: Tibsovo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
Lead Product(s) : Ivosidenib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Servier Receives a Positive CHMP Opinion For Tibsovo® in IDH1-Mutated Acute Myeloid Leukemia (AML...
Details : Tibsovo (ivosidenib) is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. In patients with AML, susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leu...
Brand Name : Tibsovo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 24, 2023
Services
Packaging
API Manufacturing
Drug Product Manufacturing
Analytical
API & Drug Product Development
Inspections and registrations
ABOUT THIS PAGE
Servier is a supplier offers 13 products (APIs, Excipients or Intermediates).
Find a price of Indapamide bulk with CEP, JDMF offered by Servier
Find a price of Perindopril Erbumine bulk with CEP, JDMF offered by Servier
Find a price of Gliclazide bulk with CEP, JDMF offered by Servier
Find a price of Ivabradine Hydrochloride bulk with DMF, JDMF offered by Servier
Find a price of Captopril bulk with DMF offered by Servier
Find a price of Hexahydroazepine bulk with DMF offered by Servier
Find a price of Perindopril Arginine bulk with DMF offered by Servier
Find a price of Perindopril Erbumine bulk with CEP offered by Servier
Find a price of Rilmenidine Phosphate bulk with CEP offered by Servier
Find a price of Trimetazidine bulk with JDMF offered by Servier
Find a price of Dexfenfluramine bulk offered by Servier
Find a price of Indapamide bulk offered by Servier
Find a price of FACILITIES AND OPERATING PROCEDURES IN BOLBEC, FRANCE bulk offered by Servier
LOOKING FOR A SUPPLIER?